

Significant TR reduction. Sustained in the real world.

Results from the PASTE registry

PASTE: PASCAL for Tricuspid Regurgitation, a European registry.¹

Largest registry investigating safety and efficacy of the PASCAL repair system for T-TEER in a real-world patient population.

Jörg Hausleiter (MD, LMU University Hospital, Munich),
Principal Investigator of the PASTE registry

Mirjam Wild (MD, University Heart Center, Bad Krozingen),
Co-Investigator of the PASTE registry



On behalf of the PASTE investigators



- **Ongoing retro- and prospective** observational study (NCT05328284)
- Consecutive patients at 18 European tertiary care centres
 - Real-world patient population
 - Currently 603 patients
- **Centralized analysis** of all echocardiographic imaging (ongoing)
- **In earlier clinical experience**, the PASCAL repair system has demonstrated **significant and sustained TR reduction** to TR $\leq 2+$ in 78% of patients at a median follow-up of 173 days in the PASTE registry (n=172)¹



Interim-analysis presented at EuroPCR 2023: TR reduction and functional improvement²

Data on 380+ patients at a median follow-up of 352 days



Interim-analysis presented at PCR London Valves 2022: quality of life improvements³

Data on 53+ patients at 1-year follow-up



PASTE demonstrates

- The PASCAL repair system is a safe and feasible option for transcatheter treatment of TR
- Sustained echocardiographic and symptomatic improvement

Treat mitral and tricuspid regurgitation with the PASCAL Precision system.



Learn more at
[Edwards.com/PASCAL](https://www.edwards.com/PASCAL)

References:

1. Wild M. et al., Multicenter Experience With the Transcatheter Leaflet Repair System for Symptomatic Tricuspid Regurgitation. JACC Cardiovasc Interv. 2022 Jul 11;15(13):1352-1363.
2. J. Hausleiter. Clinical Experience with the PASCAL Platform: PASTE Registry/LMU. Edwards Lifesciences symposium, EuroPCR 2023.
3. M. Wild. Transcatheter leaflet repair for tricuspid regurgitation: one-year results from the PASTE registry. PCR London Valves 2022.

TR: tricuspid regurgitation, NYHA: New York Heart Association, 6MWD: 6-minute walking distance, MLHFQ: Minnesota Living with Heart Failure Questionnaire, T-TEER: Tricuspid Transcatheter Edge-to-Edge Repair.

Expert opinions, advice and all other information expressed represent contributors' views and not necessarily those of Edwards Lifesciences.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult [eifu.edwards.com](https://www.edwards.com) where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, and PASCAL are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2023 Edwards Lifesciences Corporation. All rights reserved. PP--EU-6243 v1.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • [edwards.com](https://www.edwards.com)



Edwards